Navigation Links
New insights into inflammation in osteoarthritis
Date:10/28/2007

ugh desirable in health could have unfortunate consequences if the enthesis was damaged.

To validate the widespread formation and to explore further, the possible inflammatory function of SECs, researchers collected ligament and tendon attachment samples from 60 cadavers, 35 male and 25 female, with a mean age of 84 years at death. 49 different entheses19 from the arms, 26 from the legs, and 4 from the spinal columnwere preserved for examination. To exclude cartilage degeneration as a trigger for synovial inflammation, 17 of the selected entheses were not immediately adjacent to joint cartilage. Each sample was studied for evidence of inflammatory cells and soft tissue microdamage, as well as for the composition of SECs.

At 82 percent of the entheses, the formation of a SEC was found. As expected, this occurred in entheses very close to joint cartilage, where the synovium was often part of the joint itself. However, a SEC was also detected in 47 percent of the sites separated from joint cartilage. For example, the SEC found at the Achilles tendon was formed with synovium that protruded from a cavity called a bursa, located a considerable distance from the ankle joint.

Joint insertions are sites of high mechanical stressing and the authors speculated that this could lead to damage within them, including their fibrocartilage This is exactly what the authors found. Degenerative changesat least one and sometimes severalwere detected on the soft tissue side of attachment sites. Most notably, cell clustering and/or fissuring was found in 76 percent of entheses. In 85 percent of SECs, the synovial component also showed evidence of mild inflammatory change. Finally, in 73 percent of the attachments, small numbers of inflammatory cells were present in the enthesis itself. Therefore the authors suggest that joint degeneration of fibrocartilage at insertions could trigger inflammation within SECs.

As Professors Benjamin
'/>"/>

Contact: Amy Molnar
amolnar@wiley.com
John Wiley & Sons, Inc.
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. New insights into herbal supplements
2. Wrinkle reduction cream has offered insights into working of nervous system
3. Study Offers Insights Into Treatment Of Rheumatoid Arthritis
4. Reindeer Provide Valuable Insights Into Sleep Disorders
5. New Insights into Antimalarial Drug Resistance
6. Insights Into Lead Pollution
7. Insights into Osteosarcoma in Cats and Dogs may Improve Palliative Care
8. Neural Basis of Anxiety: Newer Insights
9. New Insights into Chronic Inflammation and Atherosclerosis
10. Rare Womens Lung Disease May Yield Insights Into Common Diseases
11. Insights into Acute Promyelocytic Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... for Public Affairs Research has released the results of ... it means to be a quality health care provider ... Robert Wood Johnson Foundation, sheds new light on how ... and doctors, as well as the information they use ... produces new and actionable data during a crucial period ...
(Date:7/21/2014)... Western University of Health Sciences ... For” by the Chronicle of Higher Education for ... Honor Roll for the first time. , WesternU ... and Benefits, Confidence in Senior Leadership, Job Satisfaction, ... “Western University of Health Sciences is a great ...
(Date:7/21/2014)... -- Good parenting and life skills coaching seem ... a new study suggests. Inflammation is a ... to a number of illnesses, according to Northwestern ... childhood and adulthood involve excessive inflammation. The process ... and some cancers," study author Gregory Miller, a ...
(Date:7/21/2014)... A new study suggests that potential help in ... your refrigerator. The study found that regular intake ... or supplements, may help ease the condition. Researchers ... between probiotics and blood pressure. The studies involved a ... blood pressure. People who consumed probiotics had an ...
(Date:7/21/2014)... may be getting women to go to the hospital more ... shows women have longer hospital stays and are more likely ... attack. , In the study published online today in the ... from Yale School of Medicine analyzed 230,684 hospitalizations for heart ... of 1.1 million hospitalizations reported in a national database from ...
Breaking Medicine News(10 mins):Health News:National survey from AP-NORC examines perceptions of health care provider quality 2Health News:Western University of Health Sciences Elevated to “Great College to Work For” Honor Roll 2Health News:Life Skills, Parenting Classes May Cut Inflammation in Poor Kids 2Health News:Could Probiotics Help Tame High Blood Pressure? 2
... to Cover Medical Devices, ARLINGTON, Va., Nov. 2 ... Capital Markets) today announced that,Christopher Warren has joined FBR ... Analyst within its healthcare group and will,focus on the ... of experience in equity research, and we,value the disciplined, ...
... Vanda Pharmaceuticals,Inc. (Nasdaq: VNDA ) announced ... offer convertible senior notes. The decision not to ... due principally to prevailing,market conditions resulting in note ... Note Regarding Forward-Looking Statements This release contains ...
... Pa., Nov. 2 Kensey Nash Corporation,(Nasdaq: ... licensed U.S. patent,6,175,669, Optical Coherence Domain Reflectometry Guidewire, ... the intellectual,property portfolio related to its chronic total ... enhanced optical sensing capabilities,allowing it to sense locations, ...
... Just how much of the time,that sales people should be ... internal communication? Pharmaceutical sales directors agree the answer is ... for internal communication - or 6 weeks per rep,per year ... year,according to a recent research study by Best Practices, LLC. ...
... inhibitor demonstrates >99% mean decrease in HCV RNA ... with no serious adverse events-, ... the results of a 14-day Phase 1 multiple ascending,dose monotherapy study ... study, being presented as a "late-breaker" abstract at,the 58th Annual Meeting ...
... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) will announce ... 8, 2007, after market close. The announcement ... followed by a conference call and live webcast ... 4:30 p.m. Eastern. Interested parties may access the,live ...
Cached Medicine News:Health News:FBR Capital Markets Hires Senior Healthcare Analyst 2Health News:Vanda Pharmaceuticals Announces that it No Longer Intends to Offer Convertible Senior Notes 2Health News:Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform 2Health News:Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform 3Health News:New Pharmaceutical Sales Force Communication Metrics: Nearly 6 Weeks of Sales Time per Rep Wasted Each Year 2Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 2Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 3Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 4Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 5Health News:Kosan Announces November 8, 2007 Conference Call and Webcast of Third Quarter 2007 Financial Results 2
(Date:7/21/2014)... BELMONT, Calif. , July 21, 2014 /PRNewswire/ ... world,s first fluid-based accommodating intraocular lens, today announced ... Allen, Mosbacher, and Law Chair of Ophthalmology, and ... has joined the company,s Scientific Advisory Board. ... honors, including the American Academy of Ophthalmology Lifetime ...
(Date:7/21/2014)... , July 21, 2014  Zacks.com announces the list of ... Equity Research analysts discuss the latest news and events impacting ... blog include the Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH - Free ... ), Eli Lilly and Company (NYSE: LLY - Free ... and InterMune, Inc. (Nasdaq: ITMN - Free Report ). ...
(Date:7/21/2014)... , July 21, 2014   Regulus ... biopharmaceutical company leading the discovery and development of ... U.S. Food & Drug Administration (FDA) has granted ... chemically modified oligonucleotide that binds to and inhibits ... for the treatment of Alport syndrome, a life-threatening ...
Breaking Medicine Technology:PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 2PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 3PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 4The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 2The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 3The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 4The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 5The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 6The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 7Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5
... Feb. 8, 2011 DURECT Corporation (Nasdaq: ... has launched commercial sales of its Food and Drug ... injectable animal health drug utilizing DURECT,s SABER™ technology to ... on net sales of SucroMate and will supply one ...
... DIEGO, Feb. 8, 2011 Anadys Pharmaceuticals, Inc. (Nasdaq: ... the 13th Annual Bio CEO & Investor Conference on Tuesday, ...  The conference is being held at the Waldorf-Astoria Hotel in ... Officer of Anadys, will provide an overview of Anadys and ...
Cached Medicine Technology:DURECT Announces Launch of First FDA Approved SABER™-Injectable Peptide Product 2DURECT Announces Launch of First FDA Approved SABER™-Injectable Peptide Product 3Anadys Pharmaceuticals to Present at the Bio CEO & Investor Conference 2
... Apron has standard front protection. ... from the shoulders to the ... a 6" wide elastic belt. ... apron snug. Belts may be ...
... new Breast Overlay Apron ... provide extra coverage for ... adjustable velcro flaps allow ... fit, plust added coverage ...
Lap pad used to protect pelvic regions...
... necessary, the Two-Piece should be your ... comfort through more efficient distribution of ... vest comes with shoulder pads and ... well as an attached belt to ...
Medicine Products: